Related Articles
Sustained virological response by direct‑acting antivirals reduces the recurrence risk of hepatitis C‑related hepatocellular carcinoma after curative treatment
Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence
Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct‑acting antiviral treatment: All Kagawa Liver Disease Group Study
Programmed death‑ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection
Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon‑based therapy with second‑generation direct‑acting antivirals